Granulocyte colony-stimulating factor (G-CSF) as primary prophylaxis was employed in 77 (43%) patients, human recombinant erythropoietin (rhEPO) was used due to disease-related anemia in 29 (16%) patients. This evidence concerns the gene EPO and anemia (phenotype).